Content about Asthma

January 31, 2012

As of Jan. 1, asthma products like the Primatine Mist inhaler became no longer available at retail — leaving consumers with few asthma-care options in the OTC aisle. Drug Store News recently interviewed King Bio president Frank King, who is introducing a new nonprescription inhaler for asthmatics, formulated with homeopathic ingredients, called AsthmaCare under its Safecare banner of products.

AUDIO Q&A: DSN interviewed Frank King, King Bio president, who is introducing a new nonprescription inhaler for asthmatics, formulated with homeopathic ingredients, called AsthmaCare under its Safecare banner of products. As of Jan. 1, asthma products like the Primatine Mist inhaler became unavailable at retail — leaving consumers with few asthma care options in the OTC aisle.

April 15, 2014

The Food and Drug Administration on Friday announced a meeting of the Nonprescription Drugs Advisory Committee on May 2 to discuss the potential switch of Merck's Singulair Allergy tablets.

SILVER SPRING, Md. — The Food and Drug Administration on Friday announced a meeting of the Nonprescription Drugs Advisory Committee on May 2 to discuss the potential switch of Merck's Singulair Allergy tablets. 

The proposed OTC use is "temporarily relieves these symptoms due to hay fever or other upper respiratory allergies: Nasal congestion, runny nose, itchy, watery eyes, sneezing, itching of the nose.” The applicant proposes to label the product for OTC use in adults 18 years and older. 

March 26, 2014

Springtime allergy season may be delayed a few weeks this year, kicking into high gear in early April as opposed to late March due to a 2013-2014 winter characterized by extremely low temperatures and heavy snow storms.

Springtime allergy season may be delayed a few weeks this year, kicking into high gear in early April as opposed to late March due to a 2013-2014 winter characterized by extremely low temperatures and heavy snow storms. 

March 10, 2014

Aerocrine AB, a medical products company focused on improved management and care of patients with such inflammatory airway diseases as asthma, has announced that a new randomized clinical trial shows lower incidence of asthma exacerbations and increased asthma control with Fractional exhaled Nitric Oxide (FeNO)-guided anti-inflammatory treatment.

SOLNA, Sweden — Aerocrine AB, a medical products company focused on improved management and care of patients with such inflammatory airway diseases as asthma, has announced that a new randomized clinical trial shows lower incidence of asthma exacerbations and increased asthma control with Fractional exhaled Nitric Oxide (FeNO)-guided anti-inflammatory treatment.  

The study has been published on theweb site of the Journal of Allergy and Clinical Immunology: In Practice.

February 28, 2014

The Consumer Healthcare Products Association earlier this week voiced support for keeping over-the-counter bronchodilators in the OTC Monograph during a recent meeting of the Food and Drug Administration’s Nonprescription Drugs Advisory Committee.

WASHINGTON — The Consumer Healthcare Products Association earlier this week voiced support for keeping over-the-counter bronchodilators in the OTC Monograph during a recent meeting of the Food and Drug Administration’s Nonprescription Drugs Advisory Committee. 

February 26, 2014

A pair of Food and Drug Administration advisory committees on Tuesday voted against the over-the-counter sale of Armstrong Pharmaceuticals' Primatene HFA, an epinephrine inhalation aerosol indicated for the temporary relief of mild symptoms of intermittent asthma for people ages 12 years or older.

SILVER SPRING, Md. — A pair of Food and Drug Administration advisory committees on Tuesday voted against the over-the-counter sale of Armstrong Pharmaceuticals' Primatene HFA, an epinephrine inhalation aerosol indicated for the temporary relief of mild symptoms of intermittent asthma for people ages 12 years or older.

February 18, 2014

The one-time $100 million asthma-relief brand Primatene may make a comeback to the marketplace after a more than two-year hiatus.

The one-time $100 million asthma-relief brand Primatene may make a comeback to the marketplace after a more than two-year hiatus. Primatene Mist had been withdrawn from the market in December 2011 when the agency removed all inhalers containing chlorofluorocarbons from the market.

February 18, 2014

A study by researchers at the University of Nebraska Medical Center found that vitamin D as an add-on therapy could provide some relief for chronic hives, a condition with no cure and few treatment options.

OMAHA, Neb. — A study by researchers at the University of Nebraska Medical Center found that vitamin D as an add-on therapy could provide some relief for chronic hives, a condition with no cure and few treatment options.

Jill Poole, associate professor in the UNMC Department of Internal Medicine, was principal investigator of a study in the Feb. 7 edition of the Annals of Allergy, Asthma and Immunology. The two-year study looked at the role of over-the-counter vitamin D3 as a supplemental treatment for chronic hives.

January 10, 2014

The Nonprescription Drugs Advisory Committee announced it would meet February 25 to discuss data submitted by Armstrong Pharmaceuticals in support of a new drug application for the over-the-counter marketing of Primatene HFA.

SILVER SPRING, Md. — The Nonprescription Drugs Advisory Committee on Thursday announced it would meet February 25 to discuss data submitted by Armstrong Pharmaceuticals in support of a new drug application for the over-the-counter marketing of Primatene HFA, an epinephrine inhalation aerosol 125 microgram (mcg)/actuation, as a temporary reliever of mild symptoms of intermittent asthma for consumers 12 years of age and older. 

December 18, 2013

The Food and Drug Administration has approved a new drug made by GlaxoSmithKline and Theravance for treating chronic obstructive pulmonary disease, the agency said Wednesday.

SILVER SPRING, Md. — The Food and Drug Administration has approved a new drug made by GlaxoSmithKline and Theravance for treating chronic obstructive pulmonary disease, the agency said Wednesday.

The FDA announced the approval of Anoro Ellipta (umeclidinium; vilanterol inhalation powder) as a once-per-day maintenance treatment for airflow obstruction in patients with COPD, a term that encompasses chronic bronchitis and emphysema; smoking is the leading cause of COPD in the United States.

November 8, 2013

A study being presented this week at the Annual Scientific Meeting of the American College of Allergy, Asthma and Immunology found hay fever is more prevalent in children living in the southeastern and southern states, ACAAI announced Friday.

BALTIMORE — A study being presented this week at the Annual Scientific Meeting of the American College of Allergy, Asthma and Immunology found hay fever is more prevalent in children living in the southeastern and southern states, ACAAI announced Friday.

November 6, 2013

Cockroaches and rodents are common allergy and asthma triggers in the wintertime, according to a statement released Tuesday by the National Pest Management Association.

FAIRFAX, Va. — Cockroaches and rodents are common allergy and asthma triggers in the wintertime, according to a statement released Tuesday by the National Pest Management Association. 

Citing the Asthma and Allergy Foundation of America, NPMA reported that cockroach allergens are present in 63% of American homes and mouse allergens in 82%. The number of homes containing cockroach allergens increases to as many as 78% to 98%, respectively, in urban areas.

October 30, 2013

A once-daily inhaler for chronic obstructive pulmonary disease has become available, the makers of the inhaler said Wednesday.

RESEARCH TRIANGLE PARK, N.C. — A once-daily inhaler for chronic obstructive pulmonary disease has become available, the makers of the inhaler said Wednesday.

GlaxoSmithKline and Theravance announced the availability of Breo Ellipta (fluticasone furoate; vilanterol), for long-term maintenance treatment of airflow obstruction in patients with COPD, a term that encompasses chronic bronchitis and emphysema. The drug is not meant for treating acute bronchospasm or asthma, the companies said.

October 23, 2013

The Food and Drug Administration plans to complete its phase out of inhalers that contain ozone-depleting chlorofluorocarbons by the end of the year, the agency said Wednesday.

SILVER SPRING, Md. — The Food and Drug Administration plans to complete its phase out of inhalers that contain ozone-depleting chlorofluorocarbons by the end of the year, the agency said Wednesday.

October 21, 2013

Nearly 1-in-50 people in the United States are at risk of severe allergic reactions, according to a new study announced Monday by the Asthma and Allergy Foundation of America.

WASHINGTON — Nearly 1-in-50 people in the United States are at risk of severe allergic reactions, according to a new study announced Monday by the Asthma and Allergy Foundation of America.

According to the study, severe, life-threatening allergic reactions known as anaphylaxis are common in the United States, occurring in about 1.6% of the population. The rate, the study said, is probably higher, and closer to 5.1%. The study was published in the Journal of Allergy and Clinical Immunology.

September 10, 2013

A new set of guidelines from the Food and Drug Administration could bring a generic version of a respiratory drug made by GlaxoSmithKline closer to reality.

NEW YORK — A new set of guidelines from the Food and Drug Administration could bring a generic version of a respiratory drug made by GlaxoSmithKline closer to reality.

The FDA guidelines, a set of non-binding recommendations released Monday, outline studies that manufacturers can conduct to determine equivalence between GSK's Advair Diskus (fluticasone propionate; salmeterol xinafoate) and generic versions.

September 10, 2013

Homeolab is in the process of launching three chewable tablets for respiratory care: Real Relief Asthma Respiratory Care, Real Relief Asthma Nighttime and Real Relief Allergy.

MONTREAL — Homeolab is in the process of launching three chewable tablets for respiratory care: Real Relief Asthma Respiratory Care, Real Relief Asthma Nighttime and Real Relief Allergy. Retailing for a suggested S11.99, the homeopathic tablets help relieve symptoms associated with asthma, including gasping for air, difficulty breathing, wheezing, coughing and excess mucus. Since Primatene Mist had been pulled off the market at the end of 2012, there has not been a significant asthma care brand in the self-care space.

September 10, 2013

Wellco Brands' debut product Healerz For Noses was selected for Walmart's Get On The Shelf contest earlier this year.

BUFFALO, N.Y. — Wellco Brands' debut product Healerz For Noses was selected for Walmart's Get On The Shelf contest earlier this year. The product is a pain relief cream targeted to soothe the delicate skin under the nose. The formula contains lidocaine for pain relief, benzalkonium chloride antiseptic to help guard against infection and aloe for its soothing properties.

August 12, 2013

NACDS is hosting the inaugural Total Store Expo conference in Las Vegas from August 10 to 13. Below are some of our editors' picks of the hot OTC products at the show.

NACDS is hosting the inaugural Total Store Expo conference in Las Vegas from August 10 to 13. Below are some of our editors' picks of the hot OTC products at the show.

 Nic Fix

July 8, 2013

A chronic obstructive pulmonary disease and asthma drug made by Sunovion infringes Mylan's patents on a similar drug, a federal judge has ruled, Mylan said.

PITTSBURGH – A chronic obstructive pulmonary disease and asthma drug made by Sunovion infringes Mylan's patents on a similar drug, a federal judge has ruled, Mylan said Monday.

The U.S. District Court for the Southern District of New York ruled that Sunovion's Brovana (arformoterol tartrate) infringes five patents related to Perforomist (formoterol fumarate), made by Mylan Specialty, the drug maker's branded products division.

May 30, 2013

Children in the United States are more likely to experience allergies than those in other countries, according a new study.

CHICAGO — Children in the United States are more likely to experience allergies than those in other countries, according to a new study.

May 29, 2013

An Indiana University study has found that a unique omega-3 supplement derived from the New Zealand green-lipped mussel significantly improved lung function and reduced airway inflammation in asthmatics who experience exercise-induced bronchoconstriction, also called exercise-induced asthma.

BLOOMINGTON, Ind. — An Indiana University study has found that a unique omega-3 supplement derived from the New Zealand green-lipped mussel significantly improved lung function and reduced airway inflammation in asthmatics who experience exercise-induced bronchoconstriction, also called exercise-induced asthma.

May 28, 2013

A federal court has blocked Actavis from distributing its generic version of a drug for treating asthma, the company said.

PARSIPPANY, N.J. — A federal court has blocked Actavis from distributing its generic version of a drug for treating asthma, the company said.

Actavis said the U.S. Court of Appeals for the Federal Circuit had issued an injunction against Actavis' distribution of budesonide inhalation suspension at the request of AstraZeneca, which sells the drug under the trade name Pulmicort Respules.

May 13, 2013

Drug maker AstraZeneca is encouraging patients with asthma to control their disease and learn about how it may be affecting their lives as part of National Asthma and Allergy Awareness Month, which takes place in May.

WILMINGTON, Del. — Drug maker AstraZeneca is encouraging patients with asthma to control their disease and learn about how it may be affecting their lives as part of National Asthma and Allergy Awareness Month, which takes place in May.

May 10, 2013

AllerMates on Thursday launched an online community at AllerMates.com for parents and healthcare professionals to exchange experiences, seek advice, post recipes, get breaking news and alerts, make friends, share photos and videos, use the “ask the doctor platform” and create a strong support network of allies among others dealing with allergies and asthma.

NANUET, N.Y. — AllerMates on Thursday launched an online community at AllerMates.com for parents and healthcare professionals to exchange experiences, seek advice, post recipes, get breaking news and alerts, make friends, share photos and videos, use the “ask the doctor platform” and create a strong support network of allies among others dealing with allergies and asthma.